Teva's Esomeprazole Magnesium Delayed-Release Capsules, USP, AB rated to Nexium Delayed-Release CapsulesTeva Generics leads the U.S. generic pharmaceutical market in total and new prescriptions, with total prescriptions of approximately 500 million in 2014, representing 14.2% of total U.S. generic prescriptions, or one out of every seven generic prescriptions filled in the U.S.*
Teva Generics is a division of Teva Pharmaceuticals USA, a wholly-owned subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., the global leader in generics and one of the top 10 pharmaceutical companies in the world. Teva’s extensive U.S. operations are headquartered outside of Philadelphia, PA. Approximately 45% of the company’s generic revenue is generated in the U.S.
Teva’s primary competitive advantages are its ability to continually introduce new and complex generic equivalents for brand-name drug products on a timely basis, its quality, customer service, and the breadth of its product portfolio. Teva markets the broadest product line in the industry with approximately 375 generic products in more than 1,100 dosage strengths and package sizes, covering all major therapeutic categories. In combination with their portfolio, Teva’s global network capabilities have provided mutual strategic advantages to its customers.
The company aggressively pursues new research and development efforts to make better healthcare accessible to patients. As of January 22, 2015, Teva had 120 ANDAs pending FDA approval, and introduced over 20 generic products in the U.S. in 2014.
Teva introduced Linezolid Injection, AP rated to Zyvox Injection* IMS Health NPA data as of 3/2015
Address: 1090 Horsham Road
P.O. Box 1090
North Wales, PA 19454-1090